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Abstract 
 
Breast cancer is a major health problem and comprises the largest population of 
cancer survivors in the United States, estimated at 2.9 million women, accounting for 
22% of all cancer survivors (National Cancer Institute, 2013). The advances in breast 
cancer screening, diagnosis and treatment has increased the importance of survivorship 
needs. A major concern among breast cancer survivors (BCS) is sleep disturbances. This 
study used an innovative approach to examine ethnic and racial disparities in sleep 
disturbances present in BCS. In addition, this study also explored sleep disturbances 
across different races/ethnicities. This study was a secondary data analysis of baseline 
data from the supplement study of the MBSR Symptom Cluster Trial for Breast Cancer 
Survivors/ 1R01CA131080, conducted by Dr. Lengacher. Sleep was measured using the 
Pittsburgh Sleep Quality Index, sleep diary (subjective), and sleep actigraphy (objective). 
The sample consists of 79 women who had been diagnosed with breast cancer (Stage 0, I, 
II, III), completed lumpectomy and/or mastectomy, and were within 2 weeks to 2 years 
post radiation and/or chemotherapy treatment. The aims for this study were to: 1) explore 
racial/ethnic differences in objectively measured sleep patterns among BCS; 2) estimate 
and compare the correlation between objective and subjective sleep quality by 
racial/ethnic groups among BCS; 3) examine which sleep actigraphy measure appears to 
have the strongest relationship with physical and psychological symptoms; and 4) explore 
vii 
whether these relationships (i.e. between objective sleep and self-reported symptoms) 
appear to be modified by race/ethnicity.  
The first aim was conducted using analysis of variance (ANOVA) and analysis of 
covariance (ANCOVA). Results indicated that white, non Hispanic BCS had improved 
objective sleep quality compared to minority BCS. The second aim was conducted using 
Pearson’s correlation with significant correlations found between subjective and 
objective sleep onset latency (r= .310, p= .016), and total sleep time (TST) (r= .328, p= 
.011) for the white, non-Hispanic group. The third aim was conducted using Pearson’s 
correlation with significant correlations between sleep onset latency and depression (r= 
.247, p= .029); sleep efficiency and depression (r= -.233, p= .040); sleep efficiency and 
fatigue (r= -.207, p= .045); and WASO and pain (r= .277, p= .014). There were no 
significant correlations between the anxiety score and actigraphy parameters. 
Using the significant correlations from the results of the third aim, multiple 
regression analysis was conducted with age as a covariate to test the fourth aim. The main 
effect of depression on sleep efficiency was significant (p= .044) with less depression 
associated with higher sleep efficiency. The interaction term, depression by 
race/ethnicity, had a non-significant effect on sleep efficiency (p= .299). The main effect 
of pain on WASO was significant (p= .008), and increased pain was associated with 
longer WASO. The interaction term, race/ethnicity by pain, had a non-significant effect 
on WASO (p= .148). The main effect of depression predicting sleep onset latency was 
significant (p= .027), and the interaction term, depression by race/ethnicity, had a trend 
towards a significant effect (p= .092) on predicting sleep onset latency. The interaction 
between depression and race/ethnicity predicting sleep onset latency was further 
viii 
decomposed using multiple regression. The average sleep onset latency was longer in the 
minority group with high depression levels (42 minutes) compared to the white, non-
Hispanics with high depression levels (29 minutes). Race modified the effect of 
depression on sleep onset latency in this sample of BCS. 
These finding suggest that the experience of objective sleep disturbances is 
different among races/ethnicities. Additional research is needed to further explore 
racial/ethnic differences in subjective and objective sleep disturbances and its impact on 
physical and psychological symptoms among BCS. As the number of BCS continue to 
rise, it is becoming increasingly important to recognize sleep disturbances and their 
potential physical and psychological effects early in BCS, specifically in different races 
and ethnicities. It is anticipated that these findings may contribute to improved symptom 
management for women of different races and ethnicities. 
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Chapter One 
Introduction 
Background 
Breast cancer is a major health problem and comprises the largest population of 
cancer survivors in the United States, estimated at 2.9 million women, accounting for 
22% of all cancer survivors (National Cancer Institute, 2013). The risk of developing 
breast cancer is highest among white women. According to the American Cancer Society 
(2012), the incidence of breast cancer is 118.6 per 100,000 non-Hispanic white women 
compared to 102.3 per 100,000 black women. Despite lower incidence rates, mortality in 
black women is 29.7 per 100,000, higher in comparison to the mortality in non-Hispanic, 
white women of 22.1 per 100,000. The five-year survival rate for non-Hispanic, white 
women (91%) is higher in comparison to Hispanic (86%) and black (79%) women. With 
the increasing number of breast cancer survivors (BCS), it is imperative to explore 
symptoms that may be related to the cancer diagnosis or treatment type.  
Sleep disturbances are becoming an increasingly recognized side effect of cancer 
treatment affecting both physiological and psychological functioning. These disturbances 
are characterized by difficulty falling asleep, staying asleep, early morning awakenings, 
non-restorative sleep, and daytime sleepiness (Moore et al., 2011). Sleep disturbances can 
be measured both subjectively and objectively. Objective measures of sleep disturbance 
include sleep latency, efficiency, duration, and daytime dysfunction (Alfano et al., 2011).  
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Estimates of subjective sleep disturbances vary widely, ranging between 20% to 70% of 
newly diagnosed or recently treated breast cancer patients, which is double compared to 
the general population (Fiorentino et al., 2011). For some breast cancer patients, the end 
of chemotherapy treatment may lead to restoration of sleep and rest patterns; however, 
for other breast cancer patients, sleep disturbances may become a chronic problem 
(Kotronous et al., 2012). Savard and colleagues (2001) reported that 58% of BCS who 
were approximately four years post diagnosis still reported problems related to sleep. In 
addition, breast cancer patients who completed radiation therapy, experienced sleep 
maintenance problems persisting for six months (Dhruva et al., 2012).  
Race and ethnicity are considered significant predictors of symptoms in BCS 
(Deimling et al., 2006). The Women’s Health Initiative (WHI) study found that black 
BCS had worse scores on many domains of physical functioning and general health in 
comparison to white survivors (Paskett et al., 2009). Eversley and colleagues (2005) 
conducted an interview on 116 BCS to determine racial and ethnic differences in the 
range and number of post-treatment symptoms among women who have undergone 
surgical and post-surgical treatment for breast cancer. Black BCS were more likely to 
report pain. In addition, 52% of the sample reported levels of depressive symptoms 
sufficient to be considered clinically depressed.  
Understanding the functional consequences of sleep disturbances in BCS is 
pertinent. Fatigue is a common behavioral consequence of sleep disturbances reported by 
cancer survivors and leads to decrements in the overall quality of life in BCS (Taylor et 
al., 2011). Palesh and colleagues (2010) found that BCS with sleep disturbances had 
significantly higher levels of fatigue compared to BCS without sleep disturbances. 
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Additionally, fatigue is a significant problem for minority BCS compared with white 
survivors (Von et al., 2012). It is also one of the strongest predictors of overall quality of 
life in BCS. A relationship between sleep quality, physical and psychological symptoms 
has long been recognized, but mostly in the context of white, non-Hispanic BCS. Past 
research has looked at the associations between demographic (age, education) and 
clinical (stage of disease, number of comorbidities) variables with sleep measures, but not 
between symptoms and objective sleep measures in different races/ethnicities (Beck et 
al., 2010; Enderlin et al., 2011). Additional research is needed to understand how 
race/ethnicity modifies the effect of physical and psychological symptoms on sleep in 
minority BCS.  
Statement of the Problem 
Limited research has been conducted on both objective and subjective sleep 
quality in BCS of different ethnicities and races. Despite an increasing interest in sleep 
patterns in cancer survivors, past research has focused on predominantly white samples, 
limiting information on the unique health-related quality of life outcomes of BCS of 
minority races/ethnicities. To gain a more comprehensive understanding of racial/ethnic 
differences in sleep disturbances and the effect of physical and psychological symptoms 
on objective sleep quality in BCS, additional research is needed in this area. Previous 
studies have largely relied on self-report to measure sleep, whereas objective measures of 
sleep have rarely been investigated in different races/ethnicities (Parente et al., 2012). As 
the number of BCS continue to increase, it is becoming increasingly important to fully 
characterize quality of sleep data in racial and ethnic minorities (i.e. white, non-Hispanics 
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versus other races and ethnicities) by using a comprehensive sleep assessment and further 
exploring symptoms associated with sleep in BCS. 
Statement of the Purpose 
The purpose of this cross-sectional, pilot study is to examine the relationship 
between sleep disturbances and physical and psychological symptoms across different 
races/ethnicities among BCS. Sleep disturbances are measured subjectively and 
objectively. Physical symptoms include pain and fatigue. Psychological symptoms 
include anxiety and depression. This study is a secondary data analysis of data from the 
NCI administrative sleep supplement study of the MBSR Symptom Cluster Trial for 
Breast Cancer Survivors/ 1R01CA131080, conducted by Dr. Cecile Lengacher.  
Rationale for Study 
Examining whether race/ethnicity modifies the relationship between sleep 
disturbance and physical and psychological symptoms will contribute to understanding 
the survivorship experience for specific races/ethnicities in order to proactively assess 
difficulties and plan interventions. This study is warranted due to the limited empirical 
knowledge regarding sleep disturbances in ethnic/racial minorities. Although previous 
studies have examined sleep disturbances in BCS, none has compared sleep disturbances 
in BCS from different races/ethnicities. This study is innovative as it looked at the 
modifying effect of race/ethnicity on the association between objective sleep and physical 
(i.e. pain and fatigue) and psychological (i.e. depression and anxiety) symptoms in BCS. 
Routine assessment of sleep as part of survivorship care may help to improve quality of 
life and may lessen the gap of health disparities. 
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Specific Aims 
A cross-sectional, pilot study was conducted among 79 BCS who had undergone 
surgery (lumpectomy and/or mastectomy) and treatment (radiation and/or chemotherapy) 
in the past two years. The specific aims were to: 
Aim 1: Explore racial/ethnic differences in objectively measured sleep patterns among 
BCS. 
Aim 2: Estimate and compare the correlations between objective and subjective sleep 
quality by racial/ethnic groups among BCS. 
Aim 3: Examine which sleep actigraphy measure appears to have the strongest 
relationship with physical and psychological symptoms. 
Aim 4: Explore whether these relationships (i.e. between objective sleep and self-reported 
symptoms) appear to be modified by race/ethnicity. 
Definition of Terms 
The following terms are defined and were used throughout the study.  
Cancer Survivor. Cancer survivor is defined as anyone who has been diagnosed with 
cancer, from the time of diagnosis through the balance of his or her life (National Cancer 
Institute, 2013). 
Sleep Disturbances. Sleep disturbances are characterized by difficulty falling asleep, 
staying asleep, early morning awakenings, non-restorative sleep, and/or daytime 
sleepiness (Moore et al., 2011). Subjective sleep quality was operationalized using the 
Pittsburgh Sleep Quality Index (PSQI) with a score of 5 or higher indicative of poor sleep 
quality (Buysse et al., 1989). The Actiwatch-Score actigraph was used for the objective 
assessment of sleep. 
 6 
Fatigue. Fatigue is described as a distressing condition marked by extreme tiredness and 
inability to function due to a lack of energy (National Cancer Institute, 2013). Fatigue 
was operationalized using the Fatigue Symptom Inventory (Hann et al., 1998). Higher 
scores are indicative of greater fatigue. 
Pain. Pain is defined as an unpleasant, subjective, sensory and emotional experience 
associated with tissue damage (National Cancer Institute, 2012). The Brief Pain 
Inventory (BPI) Short Form was used to assess pain and its impact on daily functions 
(Cleeland, 1991). Mild pain is defined as a worst pain score of 1 - 4, moderate pain is 
defined as a worst pain score of 5 - 6, and severe pain is defined as a worst pain score of 
7 – 10. 
Depression. Depression is defined as a mental condition characterized by ongoing 
feelings of sadness, despair, loss of energy, and difficulty dealing with daily life 
(National Cancer Institute, 2013). Self-reported depressive symptoms were measured 
with the Center for Epidemiologic Studies-Depression Scale with a score of 16 or higher 
indicative of clinical depression (Radloff, 1977).  
Anxiety. Anxiety is characterized by feelings of fear, dread, and uneasiness occurring as a 
result of stress (National Cancer Institute, 2013). The State Trait Anxiety Inventory-State 
Scale only (STAI) was used to measure anxiety (Spielberger, Gorsuch & Luschene, 
1983). Scores range from 20 to 80 with higher scores indicative of greater anxiety. 
Race. Race is based on self-report and is a social category characterized by similar 
physical experience (Heurtin-Roberts, 2004). For the purposes of this study, categories 
include white, non-Hispanic versus other races/ethnicities. 
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Significance of Study 
This study used an innovative approach to compare sleep disparities among BCS 
of different races and ethnicities. Actigraphy was utilized as an objective measure of 
sleep. This study examined which sleep actigraphy measure appeared to have the 
strongest relationship with physical and psychological symptoms. Moreover, this study 
explored if these relationships appear to be modified by race/ethnicity. This study is 
important in that it enhances a greater understanding of racial/ethnic differences in sleep 
disturbances and their relationship with physical and psychological symptoms among 
BCS. It is anticipated that the findings may contribute to greater recognition of sleep 
disturbances and improved symptom management for BCS of different races and 
ethnicities. 
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Chapter Two 
Literature Review 
Introduction 
This chapter presents the hypothesized research model and the empirical review 
of the literature. The review of literature focuses on sleep disturbances, objective sleep, 
physical and psychological symptoms in breast cancer. Finally, a summary of the 
literature review is presented. 
Hypothesized Research Model 
The hypothesized research model for this study is depicted in Figure 1. This 
model was designed to examine the specific outcome variables of interest, including 
subjective sleep quality, objective sleep disturbances, as well as the moderating effect of 
race/ethnicity on these outcome variables. The independent variables comprised of the 
study subject’s baseline physical (i.e., pain and fatigue) and psychological symptoms 
(i.e., depression and anxiety). These relationships are hypothesized based on a review of 
empirical literature. 
The proposed model explored four pathways as depicted in Figure 1. One 
pathway explored objective sleep disturbances across different races/ethnicities (i.e. 
white, non-Hispanics versus other races/ethnicities). Another pathway compared the 
correlation between subjective sleep quality and objective sleep disturbances by 
racial/ethnic differences. Another pathway explored which sleep actigraphy parameter 
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had the strongest relationship with physical and psychological symptoms. The fourth 
pathway explored whether these relationships (i.e. between objective sleep and self-
reported symptoms) appear to be modified by race/ethnicity.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Hypothesized Research Model 
Review of Empirical Literature 
Sleep disturbances are becoming an increasingly recognized side effect of 
treatment in cancer survivors. This symptom is commonly associated with other 
symptoms including pain, fatigue, depression, and anxiety (Dhruva et al., 2012). The 
following review of literature focuses on subjective sleep disturbances and breast cancer; 
objective sleep in cancer patients; physical symptoms and breast cancer; psychological 
Physical 
Symptoms: 
Pain & 
Fatigue 
Psychological 
Symptoms: 
Depression & 
Anxiety 
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Subjective 
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Objective 
Sleep 
Disturbances 
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symptoms and breast cancer; sleep quality, race/ethnicity, and breast cancer; and ethnic/ 
racial differences in symptomatology.  
Prevalence of Subjective Sleep Disturbances in Breast Cancer. The prevalence 
of subjective sleep disturbances in BCS ranges from 20% to 70% depending on the study 
and the assessment method (Pinto & Azombuya, 2011). Two main factors associated with 
a higher risk of sleep disturbances in BCS are higher proportion of vasomotor 
symptomatology and comorbid-related conditions (Pinto & Azombuya, 2011). Colagiuri 
and colleagues (2011) found that in their sample of 3343 BCS, 60% of participants had 
problems with sleep. This is approximately 50% higher than the prevalence of 38% found 
in middle-aged women in the general population. Sleep-related problems in cancer 
patients include nighttime awakenings, need to use the bathroom, uncomfortable 
breathing, coughing, or snoring (Kotronoulas et al., 2012). Within longitudinal studies of 
patients receiving chemotherapy, the severity of sleep disturbances continued to increase 
during the third and fourth cycles, compared with prior to chemotherapy (Liu et al., 
2009). The initial nights after chemotherapy were characterized by increased sleep 
fragmentation disrupting sleep maintenance. The completion of chemotherapy may lead 
to the restoration of sleep patterns for some BC patients; however, the ongoing sleep 
disturbances suggest that these can become chronic complaints in BCS. 
Chronicity of Subjective Sleep Disturbances. The chronic effects of subjective 
sleep disturbances in BCS have been suggested in various studies. Alfano and colleagues 
(2011) conducted a longitudinal cohort study among 572 BCS to investigate the patterns 
of sleep duration change across the early BC survivorship period, demographic and 
clinical variables, and their relationships with subsequent cancer-related symptoms and 
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health related QOL. Twenty-five percent of the sample had sleep duration changes with 
5.6% reporting a temporary change, 14% reporting a late-occurring change, and 5.9% 
reporting a sustained change in sleep duration. Sustained or temporary sleep changes 
were reported by BCS who were more likely to have been treated with chemotherapy or 
who gained weight after diagnosis. Sustained sleep changes were also associated with 
greater severity, affective, and sensory aspects of fatigue (Alfano et al., 2011). 
Demographic characteristics (i.e. race/ethnicity, age, and education) were not associated 
with sleep changes in this study. 
Van Onselen and colleagues (2012) conducted a longitudinal study to identify 
distinct subgroups of patients based on self-reported sleep problems prior to and within 
six months after breast cancer surgery. Three subgroups were identified including the 
high-sustained class (55.0%) consisting of BCS who had the greatest level of sleep 
problems at baseline and throughout the study; the low sustained class (39.7%) consisting 
of BCS who had low levels of sleep problem throughout the study; and the decreasing 
class consisting of BCS who had levels of sleep problems that decreased throughout the 
study (5.3%). The decreasing and high-sustained classes had worse sleep quality, sleep- 
onset latency, sleep quantity, mid-sleep awakenings, early awakenings, and excessive 
daytime sleepiness scores compared to the low sustained class (p ! .001). Increased 
medication use was reported by the high-sustained class but not by the low sustained 
class (p ! .001). Overall, the decreasing and high-sustained classes had worse sleep 
quality in comparison to the low sustained class (both p ! .001). Women of the high-
sustained class were younger, had worse functional status, more co-morbidities, increased 
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hot flashes, and higher levels of sleep problems than the low sustained class (Van 
Onselen et al., 2012). 
Subjective Sleep Disturbances and Quality of Life. A cross-sectional study was 
conducted to determine the frequency of worse sleep quality in women prior to adjuvant 
therapy for breast cancer and whether greater sleep dysfunction uniquely predicts worse 
functional outcomes (Vargas et al., 2010). The sample consisted of 240 women with 
Stage I, II, or III breast cancer before the start of adjuvant treatment. Approximately 71% 
of the sample had PSQI global scores above the established cutoff of 5.0. The average 
PSQI score was 8.5, greater than the suggested adjusted cutoff PSQI score of 8.0 for 
cancer patients. A worse score on the PSQI sleep efficiency component was associated 
with decreased functional QOL and greater disruptions in social interactions. A worse 
score on the PSQI sleep quality component was associated with worse functional well-
being, greater fatigue intensity, and lower positive states of mind but not with greater 
disruptions in social interactions (Vargas et al., 2010). 
Using an exploratory design, Humpel and Iversen (2010) examined if there was a 
relationship between sleep disturbances, fatigue, and common effects of cancer and its 
treatments in 32 breast and 59 prostate cancer survivors. Breast cancer survivors reported 
a greater problem with sleep latency and sleep disturbances than prostate cancer survivors 
(48.4% vs. 17.2%). Younger BCS and prostate cancer survivors reported a greater 
problem with both sleep latency and sleep disturbances (Humpel & Iversen, 2010). 
Multiple regression analysis indicated that fatigue was a significant predictor, and age 
approached significance on predicting global PSQI. Sleep quality was significant while 
daytime dysfunction approached significance on predicting fatigue. These findings can be 
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compared to another cross-sectional study that assessed sleep in BCS prior to the 
initiation of chemotherapy (Phillips et al., 2011). Participants reported sleeping less than 
7 hours per night with a sleep onset of 25 minutes. An average of 83% of the time in bed 
was spent sleeping, which is lower than the 85% threshold considered a good night’s 
sleep. No significant relationships were seen between age, race, gender, or marital status 
and sleep. Demographic, clinical, and lifestyle variables did not significantly predict 
sleep quality. Sleep quality was significantly correlated to mental well-being, depression, 
fatigue, and physical well-being (Phillips et al., 2011).  
Koopman and colleagues (2002) conducted a cross sectional study to examine 
sleeping problems and their relation to depression, social support, and salivary cortisol in 
97 women with metastatic breast cancer. Sixty-three percent of the sample reported one 
or more sleep disturbances. Twenty-five percent reported problems falling asleep; 44.3% 
reported problems with waking in the night; 29.9% reported problems with waking in the 
morning; and 20.6% reported sleepiness during the day. Problems waking during the 
night were significantly correlated with greater depression and less education (p<.001). 
Problems waking up in the morning were significantly correlated with greater depression 
and less social support (p<.001). Women who reported fewer hours of sleep were also 
more likely to be those with increased depression and lower social support (p<.01). 
Rumble and colleagues (2010) examined the contribution of cancer symptoms and 
dysfunctional sleep related thoughts and behaviors to insomnia in BCS. The study used a 
within-group longitudinal research design. The sample consisted of 41 BCS who had 
been diagnosed with BC for an average of 5.85 years. Approximately 73% of BCS 
reported sleep difficulties starting after their breast cancer diagnosis, and 27% reported 
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aggravation of pre-existing sleep difficulties with their diagnosis of BC. Dysfunctional 
sleep related thoughts (i.e. worries about the consequences of insomnia) and sleep 
inhibitory behaviors (i.e. napping, extending the opportunity to sleep, staying in bed 
awake) from the previous day and night significantly predicted less efficient sleep and 
worse sleep quality that night (p< .0001). Less efficient sleep and worse sleep quality 
were significantly associated with increased nighttime pain (p= .0006) and hot flashes 
(p< .0001). Results indicated that worse sleep quality was significantly associated with 
increased pain, fatigue, and hot flashes the next day. Less efficient sleep was significantly 
associated with increased fatigue (p< .0001) and hot flashes (p= .04) the next day 
(Rumble et al., 2010). Taken together, these findings suggest that there are significant 
relationships among sleep disturbances, pain, fatigue, and hot flashes in BCS.  
Objective Sleep in Cancer Patients. Several studies have examined objective 
parameters in cancer patients. Past research on the actigraphy parameters measured in 
this study are discussed below.   
Sleep Efficiency. In adults, 85% sleep efficiency is indicative of a good night’s 
sleep (Kotronoulas et al., 2012). Wright and colleagues (2009) indicated that breast 
cancer patients with a low sleep efficiency the night before breast-conserving surgery had 
significantly higher levels of post-operative pain severity (p=0.034) and post-operative 
pain interference (p=0.015). Sleep efficiency was also strongly associated with intrusive 
thoughts about surgery. Kotronoulas and colleagues (2012) indicated that sleep efficiency 
remained within the normal range for the majority of breast cancer patients across all 
weeks of chemotherapy. The greatest differences in sleep efficiency were noted in the 
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fourth week after chemotherapy with restoration of sleep efficiency to baseline levels 
within one year of completion of chemotherapy.   
Total Sleep Time. During a twenty-four hour period, adults normally sleep 
between 420-480 minutes (Berger et al., 2003). In a sample of 55 BCS, Otte and 
colleagues (2011) found that most of the sample slept less than 360 minutes and total 
sleep time was constantly low throughout the week. In newly diagnosed breast cancer 
patients, total sleep time was also decreased before the start of treatment as indicated by a 
mean total sleep time of 343.9 minutes (Wright et al., 2009). For BCS with cancer-related 
fatigue syndrome (CRFS), total sleep time was 287.67 compared to 314.21 for those 
without CRFS (Alexander et al., 2009).   
Sleep-onset Latency. In the general population, sleep-onset latency is usually less 
than 20 minutes (Dhruva et al., 2012). BCS demonstrate greater sleep onset latency than 
individuals without cancer. In a sample of 55 early stage BCS, Otte, Payne, and 
Carpenter (2012) reported that most of the sample slept less than 360 minutes with 15% 
of sleep time spent awake. The average sleep efficiency was 78%; the mean sleep latency 
was 67 minutes; and the mean number of sleep disturbances was 24. No significant 
differences were seen in wake after sleep onset (WASO), total sleep time, sleep latency, 
or sleep disturbances across the seven days of monitoring. Sleep latency was noted to 
have the highest percentage of variation among the sleep measures (Otte et al., 2011). 
Patients with breast cancer also demonstrated significantly longer sleep onset latency (p= 
.02) compared to patients with prostate cancer (Garrett et al., 2011). Sleep onset latency 
appears to be associated with burden of disease (Enderlin et al., 2011). Mean sleep onset 
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latency for patients with metastatic breast cancer was 34.8 minutes versus 15.6 minutes 
for patients with non-metastatic breast cancer.  
Nocturnal Awakenings. During a typical night’s sleep of seven hours, healthy 
adults normally awaken two to six times (Kotronoulas et al., 2012). Greater than 85% of 
BC patients undergoing radiation therapy reported an average of 15 awakenings per night 
(Dhruva et al., 2012). Similar results were found by Berger and colleagues (2008) in their 
sample of BC patients receiving adjuvant treatment, with the average number of 
nighttime awakenings between 9 to 11. Another study found that the number of 
awakenings increased from 21 to 29 after the completion of chemotherapy in women 
with regular menstrual cycles (Rissling et al., 2011). However, BC patients with irregular 
menstrual cycles experienced a decrease in the number of awakenings (27 to 25) from 
pre- to post-chemotherapy.  
Wake after Sleep Onset. In healthy adults sleeping 420 minutes per night, wake 
after sleep onset is usually less than 10% of the total sleep duration (i.e. 42 minutes) 
(Kotronoulas, et al., 2012). A longitudinal study by Dhruva and colleagues (2012) 
reported that 46% percent of the sample of breast cancer patients undergoing radiation 
had an abnormal wake after sleep onset (i.e. more than 42 minutes). The percent of wake 
after sleep onset was higher (11% of their total sleep time), but lower in comparison to 
breast cancer patients receiving chemotherapy (24% of their total sleep time) (Ancoli-
Israel et al., 2006). Additionally, there were no improvements in wake after sleep onset 
over the six months of the study, suggesting that sleep disturbance persisted in these 
women long after radiation therapy ended.  
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Beck and colleagues (2010) completed a secondary data analysis to characterize 
sleep quality and quantity prior to and in the first three nights after initial chemotherapy 
for breast cancer. The sample consisted of women with stage I, II, or III breast cancer 
treated with anthracycline and/or cyclophosphamide-based regimens. Three nights of 
actigraphy data indicated an average wake after sleep onset of about 61 minutes per 
night. Average time in bed was greater than 480 minutes and quantity of total sleep time 
averaged between 420 to 480 minutes. Women with worse sleep at baseline had 
significantly lower physical (p< .001) and mental (p< .001) health status (Beck et al., 
2010). Longer wake episodes were significantly predicted by increased depression and 
fatigue in another study of cancer survivors (Palesh et al., 2008). 
Physical Symptoms and Breast Cancer. Two common physical symptoms 
experienced by BCS include pain and fatigue. Cancer related fatigue (CRF) is one of the 
most distressing symptom reported by cancer patients, more disruptive than pain to daily 
routines, and the strongest predictor of overall quality of life in BCS (Berger, Gerber, & 
Mayer, 2012; Meeske et al., 2007; Von et al., 2012). Previous research on fatigue, fatigue 
and sleep disturbances, pain, and pain and sleep disturbances are discussed below.  
Fatigue. Fatigue is viewed as a subjective experience. According to the National 
Cancer Institute (2013), fatigue is described as a distressing condition marked by extreme 
tiredness and inability to function due to a lack of energy. Approximately one third of 
BCS experience persistent fatigue for years after completion of treatment (Bower et al., 
2011). Correlates of cancer-related fatigue include physiological factors such as pain and 
neuroendocrine changes; psychological factors such as depression and anxiety; socio-
cultural factors such as education and cognitive response; chronobiological factors such 
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as sleep and circadian rhythms; and treatment related factors such as chemotherapy, 
radiation therapy, and some biological therapies (Ancoli-Israel, et al., 2001; Jacobsen & 
Stein, 1999; National Cancer Institute, 2012).  
Berger and colleagues (2012) conducted a descriptive study to determine 
the usual and worst severity of five common symptoms and the extent to which these  
symptoms interfere with general activity and enjoyment of life in the past seven days. 
The sample consisted of 457 BCS treated between January 1992 and December 2007.  
Subjective sleep problems (48.8%) and fatigue (47.7%) were reported as the most 
prevalent symptoms in BCS. The reported mean scores for usual levels of symptoms in 
the past seven days were the highest for subjective sleep problems (3.06), followed by 
fatigue (2.70), pain (1.38), distress (1.60), and numbness/tingling (1.49) on a scale from 0 
(none) to 10 (worst). Distress and fatigue were significantly correlated with sleep 
disturbances (p< .05) among the five symptoms. 
To determine whether biological and/or functional measures are likely to be 
associated with the development of clinically significant fatigue (CSF), Gerber and 
colleagues (2011) conducted a study on 44 BCS to document the impact of the diagnosis 
and treatment of primary breast cancer on function. Results indicated that the number of 
patients with clinically significant fatigue increased from 1 at baseline (time of diagnosis 
but prior to treatment) to 11 at a 9-month follow up visit. Breast cancer treatments were 
not significantly correlated with CSF. Menopausal status (p= .03) and increased white 
blood cell count (p= .04) were significantly correlated with CSF. Surprisingly, the total 
sleep time did not differ significantly between those with CSF (8.27 hours per night) and 
those without CSF (8.35 hours per night) (Gerber et al., 2010). 
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Fatigue and Sleep Disturbances. Past research suggests that fatigue is 
significantly associated with sleep disturbances. Alexander and colleagues (2009) 
completed a study to determine the prevalence of cancer-related fatigue syndrome 
(CRFS) in a population of disease-free BCS and to investigate the relationship between 
CRFS and clinical variables. The sample consisted of 200 BCS who completed a 
diagnostic interview for CRFS, questionnaires assessing QOL, mood, and fatigue.  
Subjects also wore a wrist actigraph for 7 days to measure activity and sleep. Thirty 
percent of the participants fulfilled the criteria for CRFS. Women with CRFS reported 
more sleep disturbances, and this was supported with actigraphy data. Actigraphy data 
showed statistically significant differences in the sleep period intervals, in mean wake 
episodes, and median longest wake episode occurring during the true sleep period 
between BCS with and without CRFS (Alexander et al., 2009). 
Dirksen and colleagues (2009) conducted a secondary data analysis to determine 
if BCS with insomnia can be categorized according to their level of fatigue. The sample 
consisted of 86 BCS with insomnia who were at least 3 months post completion of 
primary treatment. Three subgroups were identified including the exhausted (35%) 
subgroup, tired (41%) subgroup, and restored (24%) subgroup. The exhausted subgroup 
had significantly worse subjective sleep quality and lower levels of anxiety compared to 
the tired and restored subgroups (p=.001). The exhausted subgroup also reported worse 
quality of life (p=.001). The restored and tired subgroups had significantly better scores 
on physical (p=.001), emotional (p=.013), functional (p=.001), and breast cancer quality 
of life (p=.006) subscales compared to the exhausted subgroup (Dirksen et al., 2009).  
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Liu and colleagues (2012) conducted an exploratory study to determine the 
longitudinal relationship between fatigue and sleep measured both subjectively and 
objectively. The sample consisted of 97 BCS with stage I, II, or III breast cancer who 
were scheduled to receive at least four 3-week cycles of chemotherapy. Subjective sleep 
quality was poor at baseline and remained unchanged throughout their chemotherapy 
cycles. Fatigue was positively associated with both subjective sleep quality and with 
objective measures of total nap time (p< .01); fatigue was negatively associated with total 
wake time during the day (p< .01).  
Pain. The International Association of the Study of Pain defines pain as an 
unpleasant, subjective, sensory and emotional experience associated with tissue damage 
(National Cancer Institute, 2012). Breast cancer survivors have pain prevalence rates of 
25% to 60% (Miaskowski et al., 2011). This wide range can be attributed to several 
factors including the differences in the definition of pain, measures used for pain 
assessment, and whether these assessments were subjective or objective (Miaskowski et 
al., 2011).  
Pain and Sleep Disturbances. The relationship between sleep disturbances and 
pain is multifaceted and poorly understood (Stiefel & Stagno, 2004). Sleep disturbances 
in patients with chronic pain are often under-reported, under-diagnosed, and under-
treated which may then lead to the development of chronic sleep disorders in patients 
(Stiefel & Stagno, 2004). Miaskowski and colleagues (2011) conducted a longitudinal 
study among 389 BCS to characterize distinct persistent pain classes and evaluate for 
differences among these pain classes in demographic, preoperative, intraoperative, and 
postoperative characteristics. Patients were classified into no (31.7%), mild (43.4%), 
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moderate (13.3%), and severe (11.6%) pain groups based on their ratings of pain. Four 
non-modifiable demographic characteristics—younger age, less education, being non-
white, and having a lower total annual income—were associated with being in the severe 
pain class. Results from this study also found that BCS with higher levels of depressive 
symptoms (p< .0001), trait anxiety (p< .0001), sleep disturbance (p< .0001), and fatigue 
(p< .0001) were at increased risk for persistent breast pain.? 
Palesh and colleagues (2007) conducted a study on 93 women with metastatic 
breast cancer to examine depression, pain, life stress, and participation in group therapy 
and their relationship to sleep disturbances. The study was an intervention trial examining 
the effect of group therapy on their symptoms at baseline, 4, 8, and 12 months. 
Approximately 64% of the sample reported one or more sleep disturbances at baseline. 
Results showed that increased problems in getting to sleep were predicted by higher 
baseline levels of pain, increased pain intensity over time, and increased number of life 
stressors at baseline (p< .001). In addition, there was an increase in problems getting to 
sleep from baseline over the course of the 12 months even when the level of pain did not 
intensify over time. This is consistent with previous research showing that sleep 
disturbances can become chronic once they have begun, even when the original trigger is 
no longer present (Stiefel & Stagno, 2004). 
In a longitudinal study of 41 BCS who had been diagnosed with insomnia, 
increased levels of pain and fatigue, and lower levels of positive mood and dysfunctional 
sleep related thoughts were identified as consequences of sleep disturbances in this 
population. Less efficient sleep (p=0.0002) and worse sleep quality (p=0.0006) 
significantly predicted higher levels of pain and fatigue, and lower levels of positive 
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mood the next day (Rumble et al., 2010). This study suggests that the relationship 
between pain and sleep disturbances is bi-directional.  
Psychological Symptoms and Breast Cancer. Depression and anxiety are 
common psychological symptoms experienced by BCS. Depression is often unrecognized 
and difficult to diagnose in the presence of cancer because of the overlap of symptoms 
(Palesh et al., 2008). Previous research on depression, depression and sleep disturbances, 
anxiety, and anxiety and sleep disturbances are discussed below.  
Depression. The National Cancer Institute (2012) defines depression as a mental 
condition characterized by ongoing feelings of sadness, despair, loss of energy, and 
difficulty dealing with daily life. Additional symptoms of depression include feelings of 
worthlessness, loss of pleasure in activities, changes in eating or sleeping habits, and 
suicidal thoughts. Common depressive disorders in BCS include major depressive 
disorder, dysthymic disorder, and mixed depressive-anxious mood disorders (Fiorentino 
et al., 2011). Fann and colleagues (2008) reported that approximately 10% to 25% of  
depression is under-recognized and under-treated during the first year after completion of 
treatment for breast cancer patients. If left untreated, depression can result in worsened 
physical symptoms and functional impairment, as well as poor adherence to treatment. 
The first year after diagnosis, BCS are at a higher risk for depression, specifically 
younger women. Furthermore, a correlation has been found between increases in 
depressive symptoms during the first year after metastatic breast cancer treatment and 
shorter survival times (Giese-Davis et al., 2011). 
Goodwin and colleagues (2004) conducted a retrospective analysis to assess the 
effect of a prior diagnosis of depression on the diagnosis, treatment, and survival of older 
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women with breast cancer. The sample consisted of 24,696 BCS who were diagnosed 
between 1993 and 1996 and included in the Surveillance, Epidemiology and End Results 
(SEER) and Medicare linked database. Approximately 8% of BCS were diagnosed with 
depression 2 years before the diagnosis of breast cancer. Participants with a prior 
diagnosis of depression had a 42% higher risk of death from breast cancer during their 3-
year follow-up. Participants with a history of depression were significantly less likely to 
receive standard treatment and were less likely to receive chemotherapy in comparison to 
women without a prior diagnosis of depression (p< .0001) (Goodwin et al., 2004). 
Depression and Sleep Disturbances. A longitudinal study was conducted on 76 
participants to examine whether the changes in sleep problems over the course of 14 
months were predictive of changes in depressive symptoms in women with breast cancer 
after treatment (Hsiao et al., 2012). Results indicated that the initial depressive symptoms 
were significantly and positively correlated with baseline scores for sleep disturbances 
(p< .001) and anxiety (p< .001). Baseline scores of anxiety and sleep were positively 
associated with initial depressive symptoms after age, BMI, and cancer and treatment 
variables were controlled. Decreased meaning in life (p< .001) and increased cortisol 
levels (p< .012) were significantly associated with increased levels of depressive 
symptoms over the course of 14 months.  
Enderlin and colleagues (2011) conducted a study to describe objective sleep 
characteristics and examine subjective sleep quality in women aged 50 and older as 
predicted by cancer status, age, number of comorbidities, and depressed mood. The 
sample consisted of 32 women with and 35 without non-metastatic breast cancer.  
Multiple regression analysis indicated that depressed mood significantly predicted 
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subjective sleep quality in this sample but not objective sleep. Objective sleep 
characteristics were similar for both groups of BCS. Depressed mood accounted for 26% 
of the variance in subjective sleep quality. Breast cancer status, age, and number of 
comorbidities were not significant predictors of subjective sleep quality (Enderlin et al., 
2011). An additional study by Otte and colleagues (2011) was conducted to refine 
knowledge regarding prevalence, severity, and correlates of sleep-wake disturbances in 
long-term BCS compared to age-matched women without breast cancer. The sample 
consisted of 246 BCS and 246 women without breast cancer. Depression was 
significantly correlated with the prevalence and severity of sleep disturbances in both 
BCS and women without breast cancer. In summary, sleep disturbances are considered a 
symptom of depression, and early identification and treatment of depression may 
decrease the prevalence of sleep disturbances in BCS.  
Anxiety. Anxiety is also a common psychological symptom among BCS and may 
be present up to eighteen months after the completion of treatment. Anxiety can 
significantly affect the course of recovery for BCS by their associations with sleep and 
thoughts about breast cancer recurrence (Vahdaninia, Omidvari, & Montazeri, 2010).  
The National Cancer Institute (2013) characterizes anxiety as feelings of fear, dread, and 
uneasiness occurring as a result of stress. The occurrence of anxiety in BCS may be 
associated with several factors including treatment-related distress, worries regarding fear 
of death and disease recurrence, and altered body image (Vahdaninia et al., 2010). 
Anxiety and Sleep Disturbances. In a prospective study to identify the association 
between subjective sleep disturbances, anxiety, and depression, Delgado-Guay and 
colleagues (2011) reported that higher PSQI scores were significantly correlated with 
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increased levels of anxiety (p= .01) and a worse sense of well-being (p= .035). The 
sample consisted of 101 cancer patients with a median age of 60 years. The most 
common cancer diagnosis in this sample was lung cancer (21%) followed by breast 
cancer (20%), and gastrointestinal cancers (15%). Eighty six percent of the sample was 
diagnosed with sleep disturbance. Past research on anxiety and sleep disturbances in BCS 
is limited, and additional research is needed in this area.  
Sleep Quality, Race/Ethnicity, and Breast Cancer. Sleep quality and the 
experience of physical and psychological symptoms among cancer survivors may be 
different among races/ethnicities. The following is research relevant to sleep quality, 
race/ethnicity, and breast cancer; racial/ethnic differences in symptomatology; and 
relationship between subjective and objective sleep disturbances.  
Limited research has been conducted on the subject of differences in sleep quality 
in BCS of different races/ethnicities. Past research has shown that nonwhite survivors 
may have small but clinically significant decrements in QOL in comparison to white 
survivors. Palesh and colleagues (2010) conducted a prospective study to determine the 
prevalence of insomnia in cancer patients. The sample consisted of 823 cancer patients 
receiving chemotherapy. White patients reported significantly more sleep disturbances 
than nonwhite patients (p< .05). Nonwhites were 44% less likely to report sleep 
disturbances than whites. The reason for these differences in reporting sleep disturbances 
is unknown and may be explained either by true biologic differences or a response bias 
(Palesh et al., 2010). 
Von and colleagues (2012) conducted a study of sleep and quality of life on 62 
African American BCS and a control group of 78 African American women with no 
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history of breast cancer. African American BCS were significantly older (57.3 years 
versus 52.2 years) and had a higher body mass index (32.1 kg/m2 versus 29.6 kg/m2) in 
comparison to the healthy comparison group. African American BCS experienced 
significantly more fatigue (p= .004) and worse hot flashes (p< .001). African American 
BCS also reported worse sleep quality (p< .001), but similar depressive symptoms and 
overall well being compared to the control group (Von et al., 2012).  
Rumble and colleagues (2011) conducted a descriptive study to report the 
prevalence of subjective sleep disturbance in a sample of African American BCS and to 
determine the extent to which sleep disturbances contribute to fatigue. The sample 
consisted of 51 African American, Afro-Caribbean, or African BCS with a mean age of 
64.2 years. Forty-three percent of the sample reported significant difficulties with sleep. 
These sleep-related difficulties included problems falling asleep and maintaining sleep, 
early morning awakenings, and dissatisfaction with sleep. An additional study was 
conducted on 51 African American BCS to report the prevalence of sleep disturbances 
(Taylor et al., 2012). The sample consisted of African!American, Afro!Caribbean or 
African BCS who were on average 7.2 years since the time of diagnosis. The most 
commonly identified sleep complaints include sleep maintenance (36%), dissatisfaction 
with sleep (35.3%), difficulty falling asleep (23.5%), and early morning awakenings 
(22.4%). After controlling for demographic and disease characteristics, insomnia 
symptom severity significantly predicted fatigue (! = .32, p< .05) and accounted for 8% 
of the variance in the fatigue scores (Taylor et al., 2012). 
Racial/Ethnic Differences in Symptomatology. Symptoms associated with 
breast cancer diagnosis and treatment vary by different races/ethnicities. In a cross-
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sectional study of 199 cancer survivors to examine cancer-related chronic pain and its 
impact on quality of life, surgery and cancer treatment were identified as the sources of 
pain for whites and blacks respectively (Green et al., 2011). Blacks experienced more 
pain interference and disability (p< .05) compared to whites. Black BCS were more likely 
to have chemotherapy and less likely to have surgery compared to whites. Miaskowski 
and colleagues (2011) reported that non-white patients were more likely to be diagnosed 
with more advanced disease (p= .009) contributing to more severe pain. Pain associated 
with cancer may be associated with an increased morbidity and diminished quality of life 
for black women consistent with an unequal burden of cancer, pain, and cancer-related 
chronic pain (Green et al., 2011). 
Deimling and colleagues (2006) conducted a descriptive study to examine anxiety 
and depression in 321 long-term cancer survivors. The purpose of this study was to 
determine the cancer-related health worries of older adults and long-term cancer 
survivors. Approximately 33% of the sample continued to report worries about cancer 
recurrence, worries about a second cancer, and worries that symptoms they experience 
may be associated with cancer. Results showed that cancer-related health worries were a 
significant predictor of both depression (!= .36) and anxiety (!= .21). Race/ethnicity was 
a significant predictor of cancer-related health worries. African American race was 
related to fewer cancer-related health worries (!= -.22) (Deimling et al., 2006). Results 
from the Women’s Health Initiative-Observational Study indicated that African 
American BCS reported lower physical functioning (p< .001), general health, (p < .001), 
and greater role limitations due to emotional health (p= .001) compared with white 
survivors. 
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Fu and colleagues (2009) administered a survey to assess the prevalence of 16 
physical and emotional symptoms and identify socio-demographic factors associated with 
these symptoms. Of the 139 BCS surveyed, 63 were Hispanic, 58 white, and 18 black. 
Fatigue (76%) was the most common symptom followed by muscle aches (40%). Most 
women reported greater than 6 symptoms. Hispanic women reported more than likely to 
report greater than 10 symptoms (p< .05), more chemotherapy-related symptoms (p < 
.05), and more pain-related symptoms (p < .05). Symptoms experienced by BCS are 
affected by their race/ethnicity with increased symptom prevalence in minorities 
compared to white BCS.  
Relationship Between Subjective and Objective Sleep. Previous research has 
indicated conflicting results of the correlations between subjective and objective 
measures of sleep disturbance. Lauderdale and colleagues (2008) reported that mean 
objective sleep explained 20% of the variation in subjective sleep. Subjective reports of 
sleep were approximately 34 minutes greater than objective sleep. This suggests that a 
moderate correlation exists between subjective reports of sleep and actigraph-measured 
sleep, but is biased by over-reporting suggesting that the true associations between sleep 
duration and health may differ from previous results (Lauderdale et al., 2008). Grutsch 
and colleagues (2011) investigated the relationship between actigraphic measurement of 
sleep and self-reported subjective sleep quality.  Results indicated that the actigraphy 
parameters (i.e. total sleep time, sleep efficiency, wake after sleep onset) were 
significantly correlated with subjective sleep quality (p< .05). The largest correlation (r= 
.62, p< .004) was noted between wake after sleep onset and PSQI. Currently, both types 
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of measures are recommended to evaluate sleep disturbances in BC patients (Lauderdale 
et al., 2008). 
Summary. In summary, across the various symptoms experienced by BCS, sleep 
disturbances is one of the most prevalent. Sleep disturbance is associated with an 
increased frequency of fatigue, pain, depression, and anxiety in BCS. Non-white BCS 
were more likely to be diagnosed with more advanced cancer contributing to more severe 
symptoms (Miaskowski et al., 2011). Previous research on sleep actigraphy parameters 
indicated that total sleep time was decreased; sleep onset latency, nocturnal awakenings, 
and wake after sleep onset were increased in BCS compared to the general population. 
These studies have focused on predominantly white samples with limited research on the 
differences between races/ethnicities. This research study is significant in that it explores 
racial/ethnic differences in objectively measured sleep patterns among BCS and examines 
which sleep actigraphy measure appears to have the strongest relationship with physical 
and psychological symptoms; and whether these relationships are modified by 
race/ethnicity. This study is warranted due to the limited empirical knowledge regarding 
the quality of life in BCS from minority populations. Past research has focused primarily 
on white, non-Hispanic BCS, and it is becoming increasingly important to take into 
consideration women of minorities as they compromise a large portion of the BCS 
population. The results from this study can be used to serve as a foundation for future 
studies exploring physical and psychological symptoms related to sleep disturbances in 
BCS from minority populations.  
Subjective and objective sleep is worse in BCS than the general population. From 
the current review of sleep disturbances in BCS of different races/ethnicities, it appears 
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that black BCS demonstrate poor objective sleep but are less likely to report subjective 
sleep disturbances compared to white cancer survivors. However, data are sparse in BCS 
and nearly non-existent in BCS of other racial and ethnic minorities. Sleep is a concern 
because it is associated with physical and psychological morbidity including pain, 
fatigue, depression, and anxiety. 
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Chapter Three 
Methods 
Introduction 
Chapter three describes the research methods and procedures for this study. The 
purpose of this study was to examine the relationship between subjective sleep quality 
and objective sleep disturbances across different races/ethnicities among BCS. The 
purpose was also to examine which sleep actigraphy measure appeared to have the 
strongest relationship with physical and psychological symptoms, and whether these 
relationships were modified by race/ethnicity. The research design is discussed first. This 
is followed by a description of the setting, sample, instrumentation, procedures, data 
management, and data analysis procedures. 
Research Design 
A cross-sectional research design was used to conduct a secondary data analysis 
of data from the NCI administrative sleep supplement study of the MBSR Symptom 
Cluster Trial for Breast Cancer Survivors/ 1R01CA131080, conducted by Dr. Cecile 
Lengacher. The current study utilized secondary data analysis on baseline data to 
examine the relationship between anxiety, depression, pain, fatigue, subjective sleep 
quality and objective sleep disturbance in BCS. 
Setting. Participants were recruited from the H. Lee Moffitt Cancer Center and 
Research Institute. Patients were also recruited from the Carol and Frank Morsani Center 
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for Advanced Health Care. Orientation assessment took place in the Survivorship Clinic 
of the Moffitt Research Center. 
Population and Sample. Three hundred and twenty-three participants consented 
to the parent R01 grant. This study included a subgroup of 79 participants who completed 
baseline actigraphic monitoring and self-report questionnaires. The inclusion criterion for 
this study were: 1) women age 21 or older; 2) diagnosis of stage 0, I, II, or III breast 
cancer; 3) completion of lumpectomy and/or mastectomy; 4) between two weeks to two 
years from end of treatment with adjuvant radiation and/or chemotherapy; 5) read and 
speak English at the 8th grade level or above; and 6) completion of baseline actigraphic 
monitoring and self-report questionnaires. Exclusion criteria consisted of the following: 
1) women who had advanced stage breast cancer (stage IV); 2) a severe current 
psychiatric diagnosis; and 3) recurrent treatment for prior breast cancer (Lengacher, 
2008). 
Instrumentation 
Demographic Data. A demographic questionnaire captured participants’ socio-
economic demographic data for a description of the sample. Data gathered included age, 
race/ethnicity, religion, highest level of education completed, marital status, employment 
status, and income.  
Clinical History. A clinical history form captured participants’ clinical data for a 
description of the sample. Data gathered include cancer diagnosis, cancer stage at time of 
diagnosis, type of breast cancer, length of time since cancer diagnosis, treatment type, 
and number of weeks on radiation/chemotherapy. 
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Subjective Sleep Disturbances. The Pittsburgh Sleep Quality Index (PSQI) was 
used to measure sleep (Buysse et al., 1989). The instrument contains 19 self-rated 
questions referring to patients’ sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, sleeping medication use, and daytime dysfunction over the 
past month. The 19 self-rated questions produce 7 component scores, scored on 4-point 
scales, which are summed up for a global PSQI score. A global PSQI score of greater 
than 5 is associated with worse sleep quality (Buysse et al., 1989).  
Objective Sleep Disturbances. The Actiwatch-Score actigraph (Philips 
Respironics, Andover, MA) was used for the objective assessment of sleep. It provides a 
noninvasive method of quantifying continuous monitoring of body movements in 
predetermined time intervals (epochs) of one minute. The actiwatch is worn on the non-
dominant wrist and is capable of detecting arm movement through the use of a 
piezoelectric accelerometer (Grutsch et al., 2011). The piezoelectric accelerometer 
monitors and stores the degree and intensity of motion, sampling every second. These 
movement data are then transferred to a computer for analysis to produce a report 
containing parameters of sleep and wake periods, their timing, duration and other 
characteristic details. Webster and colleagues (1982) reported that actigraphy scores 
correlated with EEG sleep/wake status 95% of the time and with polysomnography 
(PSG) within a range of ten percent (Berger et al., 2007). 
In accordance with recent recommendations (Berger et al., 2007), sleep 
disturbance was assessed using: 1) sleep efficiency; 2) sleep onset latency; 3) total sleep 
time; and 4) number of nighttime awakenings, specifically wake after sleep onset 
(WASO). Sleep efficiency is defined as the percentage of time in bed spent sleeping. It is 
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calculated by dividing the number of minutes of sleep by the number of minutes in bed, 
multiplied by 100. Sleep-onset latency is measured as the number of minutes between 
lying in bed and falling asleep. Total sleep time is defined as the number of minutes of 
sleep while in bed. Nocturnal awakenings refer to the number of awakenings during the 
sleep period, and wake after sleep onset specifically refers to the number of minutes 
awake after sleep onset during the sleep period (Grutsch et al., 2011). 
Fatigue. The Fatigue Symptom Inventory (FSI) was used to measure fatigue 
(Hann, Jacobsen, & Azzarello, 1998). The FSI is a 14-item self-report measure designed 
to assess severity, frequency, daily pattern of fatigue, and perceived interference with 
QOL using four indicators of fatigue on separate 11-point scales (0=Not at all; 
10=Extreme fatigue) (Hann et al.,1998). Perceived interference is a 7-item scale that uses 
separate 11-point scales to assess the degree to which fatigue in the past week was judged 
to interfere with: (i) general level of activity; (ii) ability to bathe and dress; (iii) normal 
work activity; (iv) ability to concentrate; (v) relations with others; (vi) enjoyment of life; 
and (vii) mood. These interference ratings can be summed to obtain a total perceived 
interference score. Two items measure duration of fatigue, defined as the number of days 
in the past week and the mean percentage of time each day the respondents felt fatigued. 
The final item provides qualitative information about diurnal variation in the daily 
experience of fatigue. Test-retest reliability over 3 to 12 week intervals among cancer 
patients was also favorable (r=. 35-.75). Preliminary evidence of the reliability and 
validity of the FSI has been reported for women with breast cancer. Convergent and 
divergent validity were demonstrated using correlations with the fatigue scale of the 
Profile of Mood States Fatigue and the Short-Form General Health Survey (SF-36) 
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vitality subscale (Jacobsen, 2004). The internal consistency reliability is excellent with a 
Cronbach’s alpha coefficient of greater than 0.90 (Hann et al., 1998). 
Pain. The Brief Pain Inventory (BPI) Short Form was used to assess pain and its 
impact on daily functions (Cleeland, 1991). It consists of 9 items measuring the type of 
pain, location of pain in the body, and severity of pain; pain medications and their 
usefulness in relieving pain in the past 24 hours; and the severity of pain interference in 
mood and quality of life. The Cronbach’s alpha reliability ranges from 0.77 to 0.91 
(Cleeland, 1991). 
Depression. The Center for Epidemiological Studies Depression Scale (CES-D) 
was used to measure depression (Radloff, 1977). The CES-D is a 20-item instrument that 
uses a 4-point scale, ranging from 0 = rarely or none of the time (less than 1 day) to 3 = 
most or all of the time (5-7 days), to rate how frequently depressive symptoms are 
experienced during the past week. Measures include cognitive, affective, behavioral, and 
somatic symptoms of depression, and positive affect. Cronbach’s alpha for the CES-D is 
0.92 for breast cancer subjects.  Scores range from 0 to 60 with higher calculated scores 
indicative of more severe depressive symptoms. A score of 16 or higher identified 
subjects with likely major depressive disorder (Radloff, 1977). 
Anxiety. The State Trait Anxiety Inventory-State Scale only (STAI-S) was used 
to measure anxiety (Spielberger, Gorsuch & Luschene, 1983). This is a 20-item Likert 
scale that measures state anxiety ranging from 1 (almost never) to 4 (almost always), to 
rate how respondents feel generally. The STAI-S measures an individual’s transitional 
emotional response, including worry, nervousness, tension, and feelings of apprehension 
to a stressful situation (Dhruva et al., 2012). Scores range from 20 to 80 with a score of 
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32.2 or higher are indicative of greater anxiety (Spielberger et al., 1983). The internal 
consistency reliability for the STAI is 0.95 (Spielberger et al., 1983). 
Procedure 
Approval. Approval for this study was granted by the Institutional Review Board 
at the University of South Florida (Appendix 1). This research study analyzed de-
identified data from the administrative supplement of the MBSR Symptom Cluster Trial 
for Breast Cancer Survivors/ 1R01CA131080. 
Data Collection Procedures. The current study utilized the secondary baseline 
data set from the supplement study of the R01 MBSR Symptom Cluster Trial for Breast 
Cancer Survivors. BCS who met the stated inclusion criteria were recruited from the 
Moffitt Cancer Center and Research Institute at the University of South Florida and Carol 
and Frank Morsani Center for Advanced Health Care. Health practitioners screened 
participants and provided the recruiter with a list of these patients who met the inclusion 
criteria one week prior to their scheduled appointments. Eligible patients were 
approached by the recruiter. Prior to their scheduled appointment times, patients were 
provided with a folder that contained a copy of the informed consent, the upcoming 
group schedule, and general information about the MBSR study. If interested, patients 
completed a Participant Interest Form that provided the necessary contact information 
and verified their treatment information.  
On the day of orientation, the principal investigator or a research assistant 
reviewed the informed consent with each participant before it was signed. The 
participants then completed self-reported questionnaires relevant to the various symptoms 
assessed. To ensure that all questions were answered, the questionnaires were cross-
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checked by research assistants to prevent missing data. After the completion of 
questionnaires, patients were provided the actigraphy bracelet. This device was to be 
worn on the non-dominant wrist continuously for three days (i.e. 72 hours). The 
participant was also required to fill out a Daily Time-Monitoring of Sleep Diary for each 
day. Sleep quality was measured by actigraphy in combination with patient recordings of 
bedtime and rising time. 
Data Management. Statistical Product and Services Solutions (SPSS) version 
21.0 was utilized for all data entry, data management and analysis for this study. To 
maintain patients’ confidentiality, data was de-identified and stored in password-
protected files secured in the investigator’s office. Results were reported using only de-
identified data and without patient identifiers. 
Data Analysis 
Frequency distributions and descriptive statistics were generated for sample 
characteristics. T-test and chi square analysis were used to compare sample demographic 
and clinical variables between the white, non-Hispanic versus the minority BCS. All 
socio-demographic and clinical variables with a p value of less than 0.05 were included 
as potential covariates for this study. 
Aim # 1: Explore racial/ethnic differences in objective sleep patterns among 
BCS. The predictor of interest was race/ethnicity (i.e. white, non-Hispanic versus other 
races and ethnicities) and the defined outcome measures were objective sleep pattern 
measures including sleep efficiency, sleep onset latency, total sleep time, and wake after 
sleep onset. Analysis of variance (ANOVA) was used initially to compare unadjusted 
means of the defined outcome variables between the different racial groups, whereas 
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analysis of covariance (ANCOVA) was used to compare adjusted means. Recognizing 
sample size limitations, the ANCOVA models were adjusted for age, which was a 
covariate that was imbalanced between the different racial groups. 
Aim # 2: Estimate and compare the correlations between objective and subjective 
sleep quality by racial/ethnic groups among BCS. Correlation analysis was used to 
estimate the strength of association between objective and subjective sleep quality. 
Pearson correlations were calculated if the data were normally distributed; Spearman 
correlations were calculated if the data were skewed. Correlations were calculated 
separately in white, non-Hispanics versus other racial/ethnic groups with Fisher’s r to Z 
transformation to examine confidence intervals (i.e. to normalize the distribution of the 
correlation coefficient). 
Aim # 3: Examine which sleep actigraphy measure appears to have the strongest 
relationship with physical and psychological symptoms. Pearson correlations were 
calculated between each measure of actigraphy and physical (pain and fatigue) and 
psychological (depression and anxiety) symptoms. 
Aim # 4: Explore whether these relationships appear to be modified by 
race/ethnicity. Multiple linear regression analysis was used with the most highly 
correlated actigraphy measure as the dependent variable (the best actigraphy measure 
may be different for each physical and psychological symptom); race/ethnicity and 
symptoms as main effect terms; and an interaction term for physical or psychological 
symptom by race/ethnicity. Separate models were created for each actigraphy measure. 
Power Analysis. Whereas all of the specific aims are considered exploratory, 
estimates of statistical power are provided recognizing that the primary purpose of this 
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analysis was to estimate strength of relationships and effect sizes, as opposed to the 
conduct of formal hypothesis testing. For the total sample of 79 BCS, 60 BCS (76%) 
were white, non-Hispanic and 19 (24%) were of minority race/ethnicity. The breakdown 
of the minority race was reported as: 9% (n=7) white Hispanic; 10% (n=8) black non-
Hispanic; 4% (n=3) black Hispanic; and 1% (n=1) listed their ethnicity as other. For Aim 
#1, detectable effect sizes at 80% power assuming 2-sided type I error rate of 0.05 were 
0.92 for blacks versus whites, 0.96 for Hispanics versus Non-Hispanics, and 0.75 for 
minority versus non-minority race/ethnicity. These detectable effect sizes represent 
“large” effects. For Aim #2, detectable non-zero correlations at 80% power were 0.76 for 
Hispanics, 0.74 for blacks, 0.59 for minorities, and 0.35 for non-minorities. These 
represent modest to large effects. This aim was considered exploratory in terms of 
estimating effect size (correlation). For Aim #3 and #4, in a multiple regression model 
assuming 79 subjects and 2 covariates with an R2 value of 0.15, the sample provided 80% 
power to detect an R2 value of 0.08 attributed to an objective measure of sleep actigraphy. 
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Chapter Four 
Results 
Introduction 
This chapter first presents sample descriptives followed by the study findings of 
differences in objective sleep quality between white, non-Hispanic versus minority BCS. 
It also summarizes the study findings of the moderating effect of race/ethnicity on the 
relationship between sleep actigraphy parameters and physical/psychological symptoms. 
These results are presented according to each of the four research aims. 
Participants 
The sample consisted of 79 participants of which actigraphy data was analyzed 
for 78 participants. One participant was a nightshift worker and her actigraphy data was 
not comparable to the remaining sample; however, her remaining data was analyzed. The 
racial/ethnic mix of the participants was as follows: 76% (n=60) white non-Hispanic; 9% 
(n=7) white Hispanic; 10% (n=8) black non-Hispanic; 4% (n=3) black Hispanic; and 1% 
(n=1) listed their ethnicity as other.  
Table 1 displays the mean, standard deviation, and group comparisons on age, 
marital status, education status, employment status, and annual household income for the 
white, non-Hispanic versus minority participants. The mean age of the sample was 57.0 
years with a mean age of 58.5 years for white, non-Hispanic BCS and 52.4 years for 
minority BCS. Age was the only variable that was significantly (p= .041) different 
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between the two groups and was included as a potential covariate for further analysis. 
Sixty percent of the sample was married with 60% of the white, non-Hispanic BCS 
married and 58% of the minority BCS married. Approximately 74% of the sample had 
some college degree with most of the white, non-Hispanic group (72%) and most of the 
minority group (79%) having some college degree. Approximately 37% of the sample 
was employed with 41% of the sample having an annual household income of $40,000 or 
more. 
Table 1 
Mean Age, Marital Status, Education Status, Employment Status, and Annual Household 
Income of Participants By Race/Ethnicity  
 
Variable Total  White, non-
Hispanic  
Minority  p-value 
n=79 n=60 n=19 
Mean Age + Standard 
Deviation (years) 57.1 + 9.6 58.5 + 8.6 52.4 + 11.3 0.041* 
Marital Status, n (%)    0.743 
Married 47 (59.5) 36 (60.0) 11 (57.9)  
Unmarried 32 (40.5) 24 (40.0) 8 (42.1)  
Education Status 
High School or Less 
Some College or Above 
 
21 (26.6) 
58 (73.4) 
 
17 (28.3) 
43 (71.7) 
 
4 (21.1) 
15 (78.9) 
0.531 
Employment Status    0.098 
Employed 29 (36.7) 19 (31.7) 10 (52.6)  
Not Employed 50 (63.3) 41 (68.3) 9 (47.4)  
Annual Household Income    0.434 
< $10,000 - <$40,000 47 (59.5) 32 (53.3) 13 (68.4)  
$40,000 or more 32(40.5) 28 (46.7)   6 (31.6)  
* Variable is significant at the 0.05 level. 
Table 2 displays the treatment related factors for participants. These include 
surgery type, treatment type, stage of cancer, and type of breast cancer. Forty-seven 
percent of the sample reported their type of breast cancer as carcinoma in situ. The 
majority (57%) of the sample had a mastectomy with 58% of white, non-Hispanics and 
52% of minorities having had this surgery. The most common stages of breast cancer 
were Stage 1 (34%) or Stage 2 (34%). The most prevalent stage of breast cancer in the 
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white, non-Hispanic (35%) was stage 1 compared to stage 2 in the minority (37%) group. 
The most common type of treatment in the minority group was chemotherapy and 
radiation (37%) compared to surgery only (37%) for the white, non-Hispanic group. The 
clinical variables represented in Table 2 were not statistically different by race/ethnicity 
(p> .05). 
Table 2 
Surgery Type, Treatment Type, Stage of Cancer, and Type of Breast Cancer of 
Participants by Race/Ethnicity  
 
Variable Total White, non- 
Hispanic 
Minority p value 
n=79 n=60 n=19 
Surgery Type, n (%)    0.662 
Lumpectomy 34 (43) 25 (41.7) 9 (47.4)  
Mastectomy 45 (57) 35 (58.3) 10 (52.6)  
Treatment Type, n (%)    0.403 
Chemotherapy 10 (12.7) 7 (11.7) 3 (15.8)  
Radiation 21 (26.6) 15 (25.0) 6 (31.6)  
Chemotherapy and Radiation 23 (29.1) 16 (26.7) 7 (36.8)  
Surgery only 25 (31.6) 22 (36.7) 3 (15.8)  
Cancer Stage, n (%)    0.854 
0 13 (16.5) 9 (15.0) 4 (21.1)  
1 27 (34.2) 21 (35.0) 6 (31.6)  
2 27 (34.2) 20 (33.3) 7 (36.8)  
3 12 (15.2) 10 (16.7) 2 (10.5)  
Type of Breast Cancer, n (%)    0.416 
Ductal Carcinoma In Situ 13 (16.5) 9 (15.0) 4 (21.1)  
Invasive lobular 26 (32.7) 20 (33.3) 6 (31.6)  
Invasive ductal 22 (27.8) 18 (30.0) 4 (21.1)  
Not specified 3 (4.0) 1 (1.7) 2 (10.5)  
Unknown 15 (19.0) 12 (20.0) 3 (15.7)  
     
Table 3 displays the descriptive characteristics of the actigraphy parameters, 
subjective sleep disturbance, physical and psychological symptoms. By way of 
comparison, healthy adults take less than 20 minutes on average to fall asleep, but this 
sample took an average of 26 minutes (Kotronoulas et al., 2012). Approximately 51% of 
the sample had sleep onset latency greater than 20 minutes while 49% had sleep onset 
latency within the normal range of less than 20 minutes. Healthy adults have an average 
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of about 420-480 minutes of total sleep time (Kotronoulas et al., 2012). Twenty six 
percent of the sample had total sleep time within the accepted range of 420-480 minutes, 
and 74% had total sleep time out of this accepted range. The mean was 381 minutes with 
a range of 234 to 582 minutes in this sample. Healthy adults have a sleep efficiency of 
greater than 85% (Kotronoulas et al, 2012). Approximately 78% of the sample had sleep 
efficiency below the accepted range of 85% and above, with an average sleep efficiency 
of 79%. Healthy adults have a wake after sleep onset of less than 42 minutes 
(Kotronoulas et al., 2012). Approximately 21% had wake after sleep onset within the 
normal range of less than 42 minutes, and 79 % had wake after sleep onset of greater than 
42 minutes with an average of 62 minutes. 
Table 3 
Descriptive Statistics of Actigraphy Parameters, Subjective Sleep Disturbance, Physical 
and Psychological Symptoms 
 
Variables  N Minimum Maximum Mean Standard 
Deviation 
Normal 
Range 
Percentage 
Abnormal 
Total Sleep Time  78 234 582 380.8 62.64 420-480  74.36 
Sleep Onset Latency  78 0 122 25.57 26.13 <20 51.28 
Sleep Efficiency  78 56 91 78.76 7.66 >85 78.21 
Wake after Sleep Onset  78 11 144 61.97 28.11 <42 79.49 
STAI State Scale 78 20 78 37.55 11.45 <32.2 98.72 
BPI Severity Scale 78 0 8.75 2.54 2.28 <7 6.39 
PSQI  78 1 18 8.04 4.16 <5 79.49 
FSI Severity Scale 78 0 9 4.03 1.89 <3 71.79 
CES-D   78 0 55 14.94 10.41 <16 37.18 
BPI Brief Pain Inventory Short Form, CES-D Center for Epidemiological Studies 
Depression scale, FSI Fatigue Symptom Inventory, PSQI Pittsburgh Sleep Quality Index, 
STAI-S State Trait Anxiety Inventory-State scale only. 
 
In summary, the white, non-Hispanic and minority BCS were generally similar on 
marital status, surgery type, treatment type, stage of cancer, type of breast cancer, 
education status, employment status, and annual household income. The minority group 
was significantly (p= .041) younger than the white, non-Hispanic group with a difference 
 44 
of approximately six years. Actigraphy parameters indicated that the sample of BCS had 
less total sleep time, longer sleep onset latency, worse sleep efficiency, and longer wake 
after sleep onset than the general population.  
Aim # 1 
Table 4 presents the means, standard deviations, mean differences, lower limit, 
upper limit, p values, and adjusted p values (with age as a covariate) of the actigraphy 
parameters for the white, non-Hispanic group compared to the minority group. Total 
sleep time was significantly higher for white, non-Hispanic participants (395.9 minutes) 
than for minority participants (330.4 minutes) (p= .01). The findings suggested a trend 
towards significance with minorities taking 35.7 minutes to fall asleep compared to the 
white, non-Hispanics with 22.5 minutes (p= .07). There was a non-significant trend for 
sleep efficiency to be higher in white, non-Hispanics (80%) compared to the minorities 
(76%) (p= .09). Wake after sleep onset was non-significantly higher in white, non-
Hispanics (63.7 minutes) compared to minorities (56.2 minutes) (p= .39).  
Table 4 
Means, Standard Deviations, Mean Difference, Lower and Upper Limits, and 
Significance of the Actigraphy Parameters of Participants by Race/Ethnicity  
 
Actigraphy 
Parameter 
Group N Mean Standard 
Deviation 
Mean 
Difference 
Lower 
Limit 
Upper 
Limit 
p-
value 
Adjusted 
p-value 
TST  Minority 18 330.39 57.47 -65.53 301.81 358.97 0.01 0.01* 
 White 60 395.92 56.22 -65.53 381.39 410.44     
SOL Minority 18 35.69 31.61 13.15 19.97 51.44 0.12 0.07 
 White 60 22.53 23.71 13.15 16.41 28.66     
SE Minority 18 75.93 8.59 -3.68 71.66 80.21 0.07 0.09 
 White 60 79.61 7.22 -3.68 77.75 81.48     
WASO Minority 18 56.22 26.19 -7.48 43.21 69.25 0.33 0.39 
  White 60 63.69 28.65 -7.48 56.33 71.11     
TST Total Sleep Time, SOL Sleep-onset Latency, SE Sleep Efficiency, WASO Wake after 
Sleep Onset. * Actigraphy parameter is significant at the 0.05 level. 
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Aim # 2 
Pearson correlation coefficients were used with Fisher’s r to Z transformation to 
calculate confidence intervals. Table 5 displays the Pearson correlation coefficients 
between the actigraphy parameters and self-reported measurements of sleep onset 
latency, sleep efficiency, and total sleep time as measured by PSQI. Significant 
correlations were observed between subjective and objective sleep onset latency (r= .310, 
p= .016); and between subjective and objective total sleep time (r= .328, p= .011) for 
white, non-Hispanic group. The correlations between subjective and objective sleep 
efficiency were not significant in the white, non-Hispanic and minority BCS. Because of 
the differences in the correlations between white, non-Hispanic and minority BCS, these 
correlations were further analyzed using Fisher’s r to Z transformation to examine 
confidence intervals (i.e. to normalize the distribution of the correlation coefficient). The 
confidence intervals for these correlations are also presented in Table 5. 
Table 5 
Correlations and Confidence Intervals between Objective and Subjective Sleep Onset 
Latency, Sleep Efficiency, and Total Sleep Time of Participants by Race/Ethnicity 
 
Sleep Quality Correlations Between 
Actigraphy and PSQI 
Total  White, non-
Hispanic 
Minority  
n=78 n=60 n=18 
Sleep Onset Latency 0.315** 0.310* 0.307 
 
Confidence Interval 
(p= .005) 
0.100-0.502 
(p=.016) 
0.061-0.522 
(p=.216) 
-0.186-0.676 
Sleep Efficiency 0.105 0.212 -0.12 
 (p=.359) (p=.104) (p=.636) 
Confidence Interval 
Total Sleep Time 
-0.120-0.320 
0.275* 
-0.044-0.442 
0.328* 
-0.221-0.656 
0.154 
  
Confidence Interval 
(p=.015) 
0.056 – 0.468 
(p=.011) 
0.081 -0.537 
(p=.541) 
-0.337 - 0.579 
* Correlation is significant at the 0.05 level. ** Correlation is significant at the 0.01 
level. 
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Aim # 3 
Table 6 displays the correlations between the actigraphy parameters and 
subjective measures of depression (CES-D), fatigue (FSI), pain (BPI), and anxiety 
(STAI). Significant correlations were seen between sleep onset latency and depression 
(r= .247, p= .029); sleep efficiency and depression (r= -.233, p= .040); sleep efficiency 
and pain (r= -.219, p= .049); wake after sleep onset and pain (r= .277, p= .014). There 
were no significant correlations between the anxiety score and actigraphy parameters. 
Table 6 
Correlations Between Sleep Actigraphy Parameters and Depression, Fatigue, Pain, and 
Anxiety 
 
Actigraphy Parameters Depression Fatigue Pain Anxiety 
Total Sleep Time  
 
Sleep Onset Latency 
 
Sleep Efficiency 
 
Wake after Sleep Onset 
-.026 
(p= .819) 
.247* 
(p= .029) 
-.233* 
(p= .040) 
.094 
(p= .414) 
-.124 
(p= .278) 
.166 
(p= .146) 
-.207 
(p= .070) 
.073 
(p= .527) 
.047 
(p= .680) 
.203 
(p= .075) 
-.219* 
(p= .049) 
.277* 
(p= .014) 
.048 
(p= .674) 
.159 
(p= .164) 
-.100 
(p= .384) 
-.007 
(p= .950) 
* Correlation is significant at the 0.05 level. 
 
Aim # 4 
 Multiple regression analysis was used with age as a covariate. Each model 
consists of the actigraphy parameter as the dependent variable; age as the covariate; 
race/ethnicity and physical (or psychological symptom) as the independent variables; and 
the interaction term between race/ethnicity and physical (or psychological symptom). 
Table 7 displays the results of the regression analysis for sleep efficiency with pain and 
sleep efficiency with depression. The unstandardized and standardized ! coefficients, t-
test, p value, and the adjusted R2 for each of the models are displayed in. The model 
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predicting sleep efficiency from pain, race/ethnicity, and the interaction term accounted 
for 6% of the variance in sleep efficiency. There was a trend for the main effects of both 
race/ethnicity (p= .078) and pain (p= .060) on sleep efficiency with the interaction term, 
pain by race/ethnicity, not having a significant effect on sleep efficiency (p= .118). 
White, non-Hispanic race and less pain were associated with higher sleep efficiency. The 
model predicting sleep efficiency from depression, race/ethnicity, and the interaction 
term accounted for 5% of the variance in sleep efficiency. The main effect of depression 
on sleep efficiency was significant (p= .044) with less depression associated with higher 
sleep efficiency. The interaction term, depression by race/ethnicity, had a non-significant 
effect on sleep efficiency (p= .299). 
Table 7 
Multiple Regression Analysis of Race/Ethnicity and Physical/Psychological Symptom in 
Relation to Sleep Efficiency 
 
Dependent 
Variable  
Primary 
Predictors 
Unstandardized 
Coefficient 
Standardized 
Coefficients 
T p-value  
  B Std. 
Error 
Beta      
Sleep Efficiency 
(percent) 
Intercept 78.12 5.23  14.13 14.95 0.001  
  Age (covariate) -0.01 0.09 -0.01 -0.1 0.918  
  Race/Ethnicity 3.74 2.09 0.21 1.79 0.078  
  Pain -0.72 0.38 -0.21 -1.91 0.060  
  Pain by 
Race/Ethnicity  
-1.36 0.86 -0.18 -1.58 0.118  
Adjusted R 
squared 
      0.063 
 Intercept 76.46  5.38 14.22 14.22 0.001  
 Age (covariate) 0.05 0.1 0.06 0.5 0.616  
 Race/Ethnicity 2.82 2.11 0.16 1.34 0.185  
 Depression -0.17 0.08 -0.23 -2.05 0.044*  
 Depression by  
Race/Ethnicity  
0.22 0.21 0.12 1.05 0.299  
Adjusted R 
squared 
            0.053 
* Predictor is significant at the 0.05 level. 
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Table 8 displays the results of the regression analysis for wake after sleep onset 
with pain. The unstandardized and standardized ! coefficients, t-test, p value, and the 
adjusted R2 for this model are displayed in. The model with pain, race/ethnicity, and the 
interaction term accounted for approximately 8% of the variance in wake after sleep 
onset. The main effect of pain on wake after sleep onset was significant (p= .008), and 
increased pain was associated with longer wake after sleep onset. The interaction term, 
race/ethnicity by pain, had a non-significant effect on wake after sleep onset (p= .148).  
Table 8 
Multiple Regression Analysis of Race/Ethnicity and Pain in Relation to Wake after Sleep 
Onset 
 
Dependent 
Variable 
Primary 
Predictors 
Unstandardized 
Coefficient 
Standardized 
Coefficients 
T p-value  
  B Std. 
Error 
Beta      
Wake After 
Sleep Onset 
(minutes) 
Intercept 36.88 19.04   1.94 0.057  
 Age (covariate) 0.18 0.34 0.06 0.54 0.588  
  Race/Ethnicity 7.28 7.63 0.11 0.95 0.343  
 Pain 3.73 1.37 0.30 2.73 0.008**  
  Pain by 
Race/Ethnicity  
4.59 3.14 0.17 1.46 0.148  
Adjusted R 
squared 
            0.076 
** Predictor is significant at the 0.01 level. 
Table 9 displays the results of the regression analysis for sleep onset latency with 
depression. The unstandardized and standardized ! coefficients, t-test, p value, and the 
adjusted R2 for each of the models are displayed. The model with depression, 
race/ethnicity, and the interaction term accounted for 9% of the variance in sleep onset 
latency. Depression had a significant (p= .027) main effect on sleep onset latency with 
increased depression associated with longer sleep onset latency. The interaction term, 
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depression by race/ethnicity, had a trend towards a significant effect (p= .092) on 
predicting sleep onset latency. 
Table 9 
Multiple Regression Results of Race/Ethnicity and Depression in Relation to Sleep Onset 
Latency  
 
Dependent 
Variable  
 
Primary 
Predictors 
Unstandardized 
Coefficient 
Standardized 
Coefficients 
T p-
value 
 
  B Std. 
Error 
Beta      
Sleep Onset 
Latency 
(minutes) 
Intercept 34.73 18.01   1.93 0.058  
  Age (covariate) -0.21 0.32 -0.08 -0.64 0.524  
  Race/Ethnicity -9.39 7.06 -0.15 -1.33 0.188  
  Depression 0.62 0.28 0.25 2.26 0.027*  
  Depression by 
Race/Ethnicity 
-1.23 0.72 -0.20 -1.71 0.092  
Adjusted R 
squared 
  
     
0.086 
* Predictor is significant at the 0.05 level. 
The interaction between depression and race/ethnicity predicting sleep onset 
latency was further decomposed using multiple regression. Using the median split of 
depression (CES-D score =15.00), BCS with high and low depression were compared 
based on race/ethnicity. The results of this analysis are displayed in Figure 2. Minority 
BCS with high depression (14%) showed the longest sleep onset latency (median=48 
minutes); followed by white, non-Hispanic BCS with high depression (32%; median=25 
minutes); white, non-Hispanics with low depression (44%; median=18 minutes); and 
minority with low depression (10%; median=10 minutes).  
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Figure 2. Interaction Effect of Race/Ethnicity by Depression on Sleep Onset Latency. The 
x-axis represents the different groups of the interaction term, race by depression. The 
level of depression was based on the median depression score of the each racial/ethnic 
group. The y-axis represents the sleep onset latency measured in minutes. 
 
Summary of Results 
Actigraphy parameters indicated that white, non-Hispanic BCS had better 
objective sleep compared to minority BCS. Second, the correlations between subjective 
and objective sleep onset latency and total sleep time respectively were significant in the 
white, non-Hispanic group of BCS. Of the symptoms measured, pain had a significant 
main effect on wake after sleep onset and sleep efficiency. Depression also had a 
significant main effect on sleep efficiency and sleep onset latency. However, the 
interaction effect of race/ethnicity by depression was the only interaction that had a trend 
 51 
effect on sleep onset latency. This interaction was further decomposed using multiple 
regression analysis. Results indicated that sleep onset latency was predicted by both 
race/ethnicity and depression. The average sleep onset latency was longer in the minority 
group with high depression levels (42 minutes) compared to the white, non-Hispanics 
with high levels of depression (29 minutes). Race/ethnicity modified the effect of 
depression on sleep onset latency in this sample of BCS.  
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Chapter 5 
Discussion, Conclusions, and Recommendations 
Introduction 
This final chapter presents a synthesis of the research results, with a discussion of 
the findings, conclusions, implications and recommendations for future investigation. The 
purpose of this cross-sectional, pilot study was to examine the relationship between sleep 
disturbances and physical and psychological symptoms across different races/ethnicities 
among BCS. This study used actigraphy to explore racial disparities in objective sleep 
disturbances in BCS and compared the relationships between objective and subjective 
sleep quality by racial/ethnic groups among BCS. This study also examined which sleep 
actigraphy measure had the strongest relationship with physical and psychological 
symptoms, and whether these correlations were modified by race/ethnicity.  
Summary of the Study 
This study was a secondary data analysis of the administrative sleep supplement 
study of the MBSR Symptom Cluster Trial for Breast Cancer Survivors, 1R01CA131080.  
The sample included 79 women who had been diagnosed with breast cancer (Stage 0, I, 
II, or III), completed lumpectomy and/or mastectomy, and were within 2 weeks to 2 years 
post radiation and/or chemotherapy treatment. All participants completed the 
demographic data form, PSQI, FSI, BPI, STAI-S, and CES-D on the day of orientation, 
which was scheduled at the Survivorship Clinic of the Moffitt Cancer Center and 
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Research Institute. After the completion of questionnaires, patients were provided the 
actigraphy bracelet, which was worn on the non-dominant wrist continuously for three 
days (i.e. 72 hours). Sleep quality was measured by actigraphy in combination with 
patient recordings of bedtime and rising time. Using the actigraphy data, sleep 
disturbance was assessed by the following parameters: 1) sleep efficiency; 2) sleep onset 
latency; 3) total sleep time; and 4) wake after sleep onset. Data collection took place 
before the start of the intervention. 
To explore the relationship between sleep disturbances and physical and 
psychological symptoms across different races/ethnicities among BCS, four aims were 
proposed. Analysis of variance, correlational analysis with Fisher’s r to Z transformation, 
and multiple regression analysis were used to test each aim respectively. Aims and results 
are described in detail below. 
Discussion and Conclusion 
The present study yielded four main findings. First, sleep actigraphy parameters 
indicated that white, non-Hispanic BCS had better objective sleep compared to minority 
BCS. Second, significant correlations between subjective and objective sleep parameters 
of sleep onset latency and total sleep time respectively were only seen in the white, non-
Hispanic group of BCS. Third, significant correlations were seen between sleep onset 
latency and depression, sleep efficiency and depression, sleep efficiency and pain, and 
wake after sleep onset and pain. Fourth, the interaction of race/ethnicity by depression 
had significantly predicted sleep onset latency in this sample. The following is a 
discussion of the results according to the demographics, followed by the aims in the 
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study. Limitations are discussed. The conclusions from this research study are then 
presented.  
The average age of the study participants was 57 years. Age is an important 
variable to consider when looking at racial differences in sleep disturbances, specifically 
age at diagnosis. The results of this study indicated that age was significantly (p= .041) 
different between white, non-Hispanic and minority BCS. Most of the participants in the 
current study were white, non-Hispanic, married, with some college degree, and with an 
annual income of less than $40,000. No other clinical or demographical variables differed 
between the groups, although this study may have been underpowered to detect 
differences in treatment and stage.  
The mean total sleep time of the sample was 380.8 minutes, and 74% of the 
sample had an abnormal total sleep time. This sample took longer to fall asleep with a 
mean sleep onset latency of 25.6 minutes, and 51% of the sample had an abnormal sleep 
onset latency. The mean sleep efficiency was 78.8%, and 78% of the sample had an 
abnormal sleep efficiency. The mean wake after sleep onset was 62 minutes, and 79% of 
the sample had an abnormal wake after sleep onset.  
The first aim was conducted using ANOVA to compare the means of total sleep 
time, sleep onset latency, sleep efficiency, and wake after sleep onset between white, 
non-Hispanic BCS (n=60) and minority BCS (n=18). Sleep efficiency in this study was 
lower (79% versus 90%); sleep onset latency was lower (25.6 minutes versus 34.8 
minutes); wake after sleep onset was longer (61. 9 minutes versus 37.6 minutes); and 
total sleep time was lower (380.8 minutes versus 534 minutes) than previously reported 
in a study conducted on BCS (Enderlin et al., 2011). Total sleep time was significantly 
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lower in the minority group (p= .01). There was a non-significant trend indicating 
minorities had worse sleep with higher sleep onset latency (p= .07) and lower sleep 
efficiency (p= .09). A possible explanation for this non-significant trend would be the 
small sample sizes of the minority BCS, which may have led to underestimation of 
overestimation of the differences between groups due to sample variability. A variable 
that may have been associated with the differences in sleep quality between the groups is 
the presence of hot flashes. Hot flashes have been associated with a negative effect on 
sleep quality in BCS (Rumble et al., 2010; Carpenter et al., 2012). Giedzinska and 
colleagues (2004) found that hot flashes were one of the most commonly reported 
physical symptoms for black BCS, with black BCS reporting more hot flashes than white 
BCS or Hispanic BCS. Past cross-sectional research has shown a relationship of worse 
sleep quality to pain and hot flashes in BCS (Rumble et al., 2010). In this study, data on 
hot flashes was not collected, but the prevalence of hot flashes should be considered in 
future studies.  
The second aim was conducted using correlation analysis to estimate and compare 
the correlation between objective and subjective sleep quality among BCS by 
racial/ethnic groups. The global sleep quality average of the sample was similar to that 
previously reported in another study conducted on BCS (8.03 versus 7.98) (Enderlin et 
al., 2011). The percentage of BCS exceeding the recommended PSQI cutoff score for 
poor sleep was 79% in this sample compared to 69% and 66% in previously reported 
studies of BCS (Enderlin et al., 2011; Liu et al., 2009). Significant correlations were 
observed between subjective and objective measures of sleep onset latency, total sleep 
time, but not of sleep efficiency in the white, non-Hispanic group. The correlation 
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between subjective and objective total sleep time in this study was similar to that 
previously reported (r= .41) in cancer survivors (Grutsch et al., 2011). This correlation is 
low, and may be attributed to actigraphy not being able to detect wake time in which no 
movement occurs leading to a possible overestimation of total sleep time (Blood et al., 
1997; Lockley et al., 1999). The correlations between subjective and objective sleep 
onset latency for the white, non-Hispanic (r= .310) and minority (r= .307) were of similar 
magnitude but not significant in the minority BCS. This non-significance may be 
attributed to the lack of power due to the small sample size of minority BCS. Past 
research suggests that minority patients, black patients in particular, might have more 
sleep disturbances than white patients, but they are less likely to complain of sleep 
disturbances than white participants (Durrence et al., 2006). It is unclear why minorities 
are less likely to report their sleep disturbances. Possible factors might include social 
desirability, positive coping mechanisms, and fear (Jean-Louis et al., 2009). Additional 
data must be collected to further explore this difference. 
The third aim was tested using correlational analysis to examine which sleep 
actigraphy parameter appeared to have the strongest relationship with physical and 
psychological symptoms. Sleep onset latency was significantly correlated to depression; 
sleep efficiency with depression; sleep efficiency with pain; and wake after sleep onset 
with pain. Previous research also found a significant correlation between sleep onset 
latency and the CES-D (r= .35) (Phillips et al., 2011). Limited studies have explored the 
association between sleep actigraphy parameters and these symptoms. One study that 
looked at the associations between subjective sleep disturbance and symptoms found the 
highest correlations between subjective sleep and pain (r= .270), and between sleep and 
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depression (r= .160), (Delgado-Guay et al., 2011). This study found that sleep efficiency 
was significantly correlated to depression (r=-.233) and pain (r=-.219), and showed a 
trend towards an association between sleep efficiency and fatigue (r=-.207). These 
correlations indicate that higher depression, higher fatigue, and higher pain levels are 
associated with lower sleep efficiency. Sleep efficiency was also significantly correlated 
with fatigue (r= .27) and depression (r= .40) in a sample of 78 breast cancer patients 
receiving chemotherapy (Roscoe et al., 2009). Rumble and colleagues (2010) found that 
less efficient sleep was significantly related to increased pain in their sample of 41 BCS. 
Significant negative associations were found between sleep efficiency the night before 
breast-conserving surgery and postoperative pain severity in a sample of 24 breast cancer 
patients (r=-.44) (Wright et al., 2009). It is important to mention that anxiety was not 
associated with objective sleep disturbances. These results were not supported by 
previous research, which showed a significant association between anxiety and sleep 
quality in BCS (Delgado-Guay et al., 2011; Hsiao et al., 2012).  
The results of the third aim indicate that sleep actigraphy parameters may be 
associated with specific symptoms in BCS. Past research indicates that patients 
experience an array of symptoms that often cluster together (Lengacher et al., 2012). 
These symptoms include sleep disturbance, fatigue, depressed mood, pain, anxiety, or 
stress. In a study of 78 women with gynecologic cancer, Jim and colleagues (2013) found 
that sleep disturbance, fatigue, and depressed mood occur in a cascade pattern during 
chemotherapy. Interventions targeting sleep disturbances early on during patient 
assessments may be beneficial in managing fatigue, which in turn may improve 
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depressed mood in cancer survivors. Furthermore symptoms that cluster together may 
have underlying mechanisms that should be investigated further.  
The fourth aim was conducted using multiple regression analysis to examine 
whether the relationships from the third aim were significantly modified by 
race/ethnicity. Of the symptoms, depression had a significant main effect on sleep onset 
latency with a trend towards a significant interaction between depression and 
race/ethnicity (p= .092) predicting sleep onset latency. This interaction was further 
decomposed using a median split for depression and compared BCS of high and low 
depression based on different races/ethnicities. The average sleep onset latency was 
longest in the minority group with high depression levels and shortest in the minority 
group with low depression levels. The results of this aim indicate that minority BCS who 
are also depressed may benefit from additional screening to determine if they are 
experiencing sleep disturbances.  
Limitations. Due to the small sample size, there may be large sample variability, 
which may lead to an underestimation or overestimation of the magnitude of 
relationships. Additionally, there may be a relationship in the hypothesized direction but 
the associations from the second aim were not statistically significant due to the small 
sample sizes. If there was a larger sample available, the associations from the second aim 
may have been significant. The cross-sectional design did not allow for causal 
relationships between variables to be determined. Even with the limitations, there were 
several strengths of this study. Approximately 24% of the sample was of racial/ethnic 
minority populations. It explored whether the relationships between sleep actigraphy 
parameters, physical, and psychological symptoms were modified by race/ethnicity. The 
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study was further strengthened by both the objective and subjective assessment of sleep 
disturbances. Baseline data were collected for all participants; there was no missing data. 
Because sleep disturbances are so prevalent in BCS, accurate assessment of 
subjective and objective sleep disturbances is imperative. The results of this study 
indicated that race/ethnicity had an effect on objective sleep quality; the correlation 
between subjective and objective sleep; and on the association between depression and 
sleep onset latency. Although these preliminary findings need to be replicated in larger, 
more ethnically diverse populations, the results have several important implications for 
nursing.  
Implications for Nursing  
Sleep disturbances have been indicated as a factor underlying some health 
disparities (Kachikis & Breitkopf, 2012). It cannot be assumed that BCS of different 
races sleep similarly. Replicating this study in settings highly populated with African 
American and Hispanic BCS may prove beneficial in further exploring sleep 
disturbances.   
Many BCS complain of sleep disturbances particularly before the start of 
treatment. The stress of a cancer diagnosis may contribute to difficulty sleeping prior to 
treatment. High levels of sleep disturbances co-occur with a number of symptoms such as 
fatigue and depression in women who are to undergo breast cancer surgery (Van Onselen 
et al., 2011). Additional research is needed to determine cancer-specific physiological, 
psychological, and behavioral factors that contribute to the development of sleep 
disturbances prior to and after the completion of adjuvant therapy. Additional, 
longitudinal studies are needed to further examine the physical, emotional, and 
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psychosocial experience of minority BCS to further explore the contributing factors of 
their worse outcomes (Paskett et al., 2008). Longer follow-ups are also needed to assess 
how sleep actigraphy variables evolve with the cessation of chemotherapy, radiation 
therapy, and initiation of other adjuvant treatments such as hormone therapy. 
The first step in accurate symptom management is symptom recognition (Yoon et 
al., 2008). Healthcare providers should incorporate the assessment of sleep disturbances 
early on during clinical visits. Healthcare providers in a variety of settings play a major 
role in the management of sleep disturbances-from diagnosis to treatment. For BCS 
reporting difficulty sleeping, the most frequently cited reason for not receiving help was 
that their doctors were not aware of their symptoms (Yoon et al., 2008). A greater 
percentage of minority women compared to white women reported that the doctor did not 
think treatment would benefit her (p= .02), and the doctor did not appreciate how much 
the problem bothered them (p= .03). Both black and Hispanic women indicated that they 
were not aware of resources for their sleeping problems (Yoon et al., 2008).  
Incorporating interventions as part of cancer survivorship care plan is important 
for improved quality of life of cancer survivors. Cognitive-behavioral interventions and 
behavioral therapy (BT) interventions have been effective to improve sleep quality in 
cancer survivors (Berger et al., 2009; Epstein & Dirksen, 2007). These interventions 
consist of an individualized sleep-wake schedule, stimulus control instructions, sleep 
education, and sleep hygiene. In an intervention of 219 breast cancer participants, 
clinically significant, poor subjective sleep was present in 22% of the BT group and 36% 
of the control at 90 days (p< .004) after their last chemotherapy cycle, and in 19% of the 
BT group and 28% of the control group at one year since their last chemotherapy cycle. 
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Longitudinally, BT intervention has also shown to be effective in improving sleep quality 
in breast cancer patients one year or more after the first chemotherapy cycle (Berger et 
al., 2009). Cognitive-behavioral interventions have also indicated a positive outcome on 
objective sleep with sleep efficiency increasing from 69% to 84.5% (Epstein & Dirksen, 
2007). In addition, total sleep time decreased from 434 to 407 after the completion of a 
CBT intervention (Epstein & Dirksen, 2007). Results indicated that adopting behavioral 
techniques to promote sleep may result in improved sleep and lower fatigue after 
chemotherapy, but may require earlier introduction in the cancer trajectory for maximum 
symptom management (Berger et al., 2003).  
 An additional intervention that is effective in reducing sleep disturbances is 
mindfulness meditation. Mindfulness meditation is defined as being intentionally aware 
of the surroundings, and consists of formal meditation practices for the application of this 
awareness to one’s daily activities (Shapiro & Carlson, 2009). Past research has indicated 
its effectiveness in reducing mind-racing and excessive worrying (Bootzin et al., 2010). 
In a randomized controlled study to investigate the prevalence and severity of symptoms 
and symptom clustering in BCS who attended MBSR, Lengacher and colleagues (2012) 
found that MBSR had significantly reduced fatigue and subjective sleep disturbances (p< 
.01) in their sample of 84 BCS. Future interventions should incorporate MBSR as it has 
been effective in reducing sleep disturbances and fatigue in cancer survivors. 
Mindfulness principles have also been integrated with CBT, and both have been 
beneficial in reducing arousal in patients with sleep disturbances (Bootzin & Epstein, 
2011). Results of other studies suggest that interventions targeting sleep disturbances may 
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also be beneficial in addressing symptoms associated with sleep disturbances, pain, 
fatigue, and depression (Berger et al., 2012; Lengacher et al., 2012). 
Recommendations for Future Study 
Based upon the review of relevant studies and the current study, the following 
recommendations are made for future research. 
1. Replication of the current study with a larger sample of BCS from 
different races/ethnicities. 
2. Replication of the current study with control groups of women without a 
history of cancer-both white, non-Hispanic and minority groups. 
3. Longitudinal follow up of the BCS could reveal interesting patterns of 
sleep disturbances, physical and psychological symptoms with differences 
among races/ethnicities over time. 
4.  The associations among sleep disturbances, depression, and fatigue 
suggest that these symptoms may present as clusters in cancer survivors. 
Future investigation should focus on identifying common perpetuating and 
precipitating factors of these symptom clusters in cancer survivors.  
5. Future research should incorporate more frequent, subjective and objective 
sleep assessments to better understand the variation in sleep disturbances 
over the course of survivorship. 
6. Further investigation of the underlying, biological mechanisms that lead to 
sleep disturbances in breast cancer survivors.  
7. Design culturally appropriate interventions for sleep.  
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12901 Bruce B. Downs Blvd., MDC035 ?????????????-4799 
(813) 974-5638 ?????????????-5618 
 
 
April 3, 2012 
 
Cecile A. Lengacher, RN, Ph.D. 
College of Nursing 
12901 Bruce B. Downs Blvd., MDC 22 
Tampa, FL 33612 
 
Attn:  Sophia Ramesar 
 
RE:   Modification Request  
 IRB#:  107408 
Title:  MBSR Symptom Cluster Trial for Breast Cancer Survivors 
Study Approval Period:  11/23/11  to 11/23/12 
 
Dear Dr. Lengacher: 
 
On 04/03/12/12 the Institutional Review Board (IRB) reviewed and APPROVED your Modification 
Request.   The submitted request has been approved from 04/03/12 to 11/23/12 for the following:  
 
Change in Key Personnel (the addition of Dr. J. Cox to the study). 
Revised Informed Consent, Version 10, dated 03/19/12. 
Revised Protocol dated 03/19/12. 
Allowing a doctoral study (Pinky Budhrani) access to deidentified data set for 
secondary data analysis purposes. 
 
Please note, if applicable, the enclosed informed consent/assent documents are valid during the 
period indicated by the official, IRB-Approval stamp located on page one of the form.  Valid consent 
must be documented on a copy of the most recently IRB-approved consent form.  Make copies from the 
enclosed original.   
      
Please reference the above IRB protocol number in all correspondence to the IRB or the Division of 
Research Compliance.  It is your responsibility to conduct this study in accordance with IRB policies and 
procedures and as approved by the IRB. 
 
Please note the USF IRB is moving to a fully electronic system for the maintenance of active IRB 
protocols by the end of 2012.  If you wish to continue this research after December 31,2012, this 
historical “paper” study will need to be converted into the electronic system before 12/31/2012.  
Historical “paper” studies that are still active and have not been converted into the electronic system by 
12/31/2012 will be administratively closed by the USF IRB.  To convert your paper study, please go to 
https://arc.research.usf.edu/Prod. If you have not yet registered for ARC (i.e., eIRB) you will need to do 
so prior to converting your paper study.  If your participation in this research study will end prior to 
12/31/2012, please do not convert the study to the electronic system and instead, submit a final report to 
close the study with the IRB.   
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